Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma

Kurt Jaeckle, Abraham Mittelman, Fiona H. Hill

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77 + weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58 +, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129 + weeks, respectively. Overall, median time to progres-sion and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16%). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.

Original languageEnglish (US)
Pages (from-to)1408-1418
Number of pages11
JournalJournal of Clinical Oncology
Volume8
Issue number8
DOIs
StatePublished - Jan 1 1990

Fingerprint

Serratia marcescens
Astrocytoma
Chills
Survival
Arthralgia
Erythema
Carbon Monoxide
Hypotension
Nausea
Vomiting
Headache
Fever
Radiotherapy
Observation
Technology
Drug Therapy
Injections

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jaeckle, Kurt ; Mittelman, Abraham ; Hill, Fiona H. / Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 8. pp. 1408-1418.
@article{85f30612e3944d1a8f002ffdbdb45771,
title = "Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma",
abstract = "Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77 + weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58 +, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129 + weeks, respectively. Overall, median time to progres-sion and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16{\%}). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.",
author = "Kurt Jaeckle and Abraham Mittelman and Hill, {Fiona H.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1200/JCO.1990.8.8.1408",
language = "English (US)",
volume = "8",
pages = "1408--1418",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. / Jaeckle, Kurt; Mittelman, Abraham; Hill, Fiona H.

In: Journal of Clinical Oncology, Vol. 8, No. 8, 01.01.1990, p. 1408-1418.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma

AU - Jaeckle, Kurt

AU - Mittelman, Abraham

AU - Hill, Fiona H.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77 + weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58 +, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129 + weeks, respectively. Overall, median time to progres-sion and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16%). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.

AB - Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77 + weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58 +, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129 + weeks, respectively. Overall, median time to progres-sion and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16%). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.

UR - http://www.scopus.com/inward/record.url?scp=0025076358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025076358&partnerID=8YFLogxK

U2 - 10.1200/JCO.1990.8.8.1408

DO - 10.1200/JCO.1990.8.8.1408

M3 - Article

VL - 8

SP - 1408

EP - 1418

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -